Biểu đồ giá cổ phiếu CABA
CABA Thu nhập
Cabaletta Bio Inc
$3.73
-10.12%
$-0.42
Khi đóng cửa: May 06, 16:00:00 GMT-4
$3.77
1.07%
$0.04
Phiên trước giờ: May 07, 05:29:42 GMT-4
Quay lại
Cabaletta Bio Inc (CABA) Thu nhập
Thống kê chính
Giá đóng cửa trước
$4.15
Giá mở cửa
$4.16
Phạm vi ngày
$3.53 - $4.22
Phạm vi 52 tuần
$1.06 - $3.78
Khối lượng
6.7M
Khối lượng trung bình
2.6M
Tỷ suất cổ tức
--
EPS (TTM)
-2.28
Vốn hóa thị trường
$419.6M
CABA là gì?
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 148 full-time employees. The company went IPO on 2019-10-25. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
